I am a board-certified medical oncologist who specializes in caring for people with plasma cell cancers. These include monoclonal gammopathy of undetermined significance (MGUS), asymptomatic (smoldering) multiple myeloma, and multiple myeloma requiring treatment.
As a doctor, my goal is to guide patients as we consider options for their care including the full array of clinical trials offered at MSK. My philosophy is to consider not only the details of my patients’ disease but also their priorities and quality of life, so that I can provide the right treatments for them.
My research is aimed at bringing chimeric antigen receptor (CAR) T cell therapy to people with multiple myeloma. My goal is to move the field of CAR T cell therapy forward so that we can provide the safest, most effective cellular therapy options for our patients. We expect to open a clinical trial based on my laboratory research for patients with relapsed myeloma in the first half of 2017.
- Clinical Expertise: Multiple Myeloma; Smoldering Myeloma; Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Languages Spoken: English
- Education: MD, PhD, Mount Sinai School of Medicine
- Residencies: Mount Sinai Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Medical Oncology; Internal Medicine
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more